TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T39716	Voltage-gated sodium channel alpha Nav1.5	D03HYQ	Ranolazine	Approved	56959	C24H33N3O4	427.5	CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O	IC50 = 428000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D03QWT	Doripenem	Approved	73303	C15H24N4O6S2	420.5	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O	IC50 = 1584893.19 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D05OFX	Lacosamide	Approved	219078	C13H18N2O3	250.29	CC(=O)N[C@H](COC)C(=O)NCC1=CC=CC=C1	IC50 = 501187.23 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D08CDI	Lapatinib	Approved	208908	C29H26ClFN4O4S	581.1	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	IC50 = 3162277.66 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0BP9C	Etravirine	Approved	193962	C20H15BrN6O	435.3	CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N	IC50 = 501187.23 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0CL9S	Telbivudine	Approved	159269	C10H14N2O5	242.23	CC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O	IC50 = 3162277.66 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0D7KC	Alvimopan	Approved	5488548	C25H32N2O4	424.5	C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O	IC50 = 251188.64 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0I1FQ	Raltegravir	Approved	54671008	C20H21FN6O5	444.4	.	IC50 = 316227.77 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0NR6S	Maraviroc	Approved	3002977	C29H41F2N5O	513.7	CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C	IC50 = 630957.34 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0NW3X	Dofetilide	Approved	71329	C19H27N3O5S2	441.6	CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C	IC50 > 300000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0U2JP	Sitagliptin	Approved	4369359	C16H15F6N5O	407.31	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N	IC50 = 630957.34 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0X5ZI	Ambrisentan	Approved	6918493	C22H22N2O4	378.4	CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C	IC50 = 1000000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0Z7ZM	Rhucin	Approved	135398744	C22H30N6O4S	474.6	CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C	IC50 = 501187.23 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B2GB5A	CID 58044383	Investigative	58044383	C24H18FN5O3	443.4	C1CC1C2=NN=C(O2)CN3C(=O)N4C=C(C=CC4=N3)C5=CC=C(C=C5)OC6=CC=C(C=C6)F	IC50 = 740000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B3B8IR	6-[4-(4-Fluorophenoxy)phenyl]-2H-[1,2,4]triazolo[4,3-a]pyridin-3-one	Investigative	58044433	C18H12FN3O2	321.3	C1=CC(=CC=C1C2=CN3C(=NNC3=O)C=C2)OC4=CC=C(C=C4)F	IC50 = 1903000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B67BIE	CID 58044606	Investigative	58044606	C22H16FN5O4	433.4	C1=CC(=CC=C1C2=CN3C(=NN(C3=O)CC4=NOC(=N4)CO)C=C2)OC5=CC=C(C=C5)F	IC50 = 981000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B9GP0W	CID 56596475	Investigative	56596475	C22H16FN5O3	417.4	CC1=NOC(=N1)CN2C(=O)N3C=C(C=CC3=N2)C4=CC=C(C=C4)OC5=CC=C(C=C5)F	IC50 = 215000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BD31ZR	Chembl4127600	Investigative	138319685	C22H29N3O2	367.5	C[C@]12CCC(=O)C[C@H]1C[C@H]([C@@H]2OC3=CC=C(C=C3)C#N)N4CCC[C@H](C4)N	IC50 > 300000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BGUS96	CID 56595888	Investigative	56595888	C22H16FN5O3	417.4	CC1=NC(=NO1)CN2C(=O)N3C=C(C=CC3=N2)C4=CC=C(C=C4)OC5=CC=C(C=C5)F	IC50 = 541000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BMWG84	6H-Pyrimido[5,4-b][1,4]oxazin-7(8H)-one, 2-[[[trans-4-[(1R)-1-amino-2-(7-fluoro-2-oxo-1(2H)-quinoxalinyl)ethyl]cyclohexyl]amino]methyl]-	Investigative	46206000	C23H26FN7O3	467.5	C1CC(CCC1[C@H](CN2C3=C(C=CC(=C3)F)N=CC2=O)N)NCC4=NC=C5C(=N4)NC(=O)CO5	IC50 > 333000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BVJH09	1-[(2S)-2-Amino-2-[(1r,4S)-4-[({3-oxo-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-6-yl}methyl)amino]cyclohexyl]ethyl]-7-methoxy-1,2-dihydro-1,5-naphthyridin-2-one	Investigative	46205341	C25H30N6O4	478.5	COC1=CC2=C(C=CC(=O)N2C[C@@H](C3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5)N)N=C1	IC50 > 333000 nM	Non binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D06GGT	MCL-1-specific antisense oligonucleotide + nilotinib (AMN107)	Investigative	644241	C28H22F3N7O	529.5	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	IC50 = 1000000 nM	Non binder